33.33
-0.64 (-1.90%)
| Previous Close | 33.97 |
| Open | 34.11 |
| Volume | 198,042 |
| Avg. Volume (3M) | 1,479,379 |
| Market Cap | 6,113,471,488 |
| Price / Earnings (Forward) | 1.00 |
| Price / Sales | 13.39 |
| Price / Book | 6.28 |
| 52 Weeks Range | |
| Earnings Date | 10 Mar 2025 - 14 Mar 2025 |
| Profit Margin | -66.92% |
| Operating Margin (TTM) | -43.92% |
| Diluted EPS (TTM) | -1.92 |
| Quarterly Revenue Growth (YOY) | 66.90% |
| Total Debt/Equity (MRQ) | 31.05% |
| Current Ratio (MRQ) | 4.98 |
| Operating Cash Flow (TTM) | -157.60 M |
| Levered Free Cash Flow (TTM) | -120.41 M |
| Return on Assets (TTM) | -12.28% |
| Return on Equity (TTM) | -28.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Legend Biotech Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 1.63 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 51.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ra Capital Management, L.P. | 30 Sep 2024 | 7,506,934 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 86.00 (RBC Capital, 158.07%) | Buy |
| 86.00 (Redburn Atlantic, 158.07%) | Buy | |
| Median | 84.50 (153.56%) | |
| Low | 73.00 (HC Wainwright & Co., 119.06%) | Buy |
| Average | 82.00 (146.06%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 42.31 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Dec 2024 | 73.00 (119.05%) | Buy | 37.90 |
| 13 Nov 2024 | 73.00 (119.05%) | Buy | 39.35 | |
| Cantor Fitzgerald | 09 Dec 2024 | 83.00 (149.06%) | Buy | 41.63 |
| RBC Capital | 09 Dec 2024 | 86.00 (158.06%) | Buy | 41.63 |
| 29 Oct 2024 | 86.00 (158.06%) | Buy | 45.46 | |
| Redburn Atlantic | 08 Oct 2024 | 86.00 (158.06%) | Buy | 48.06 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |